Tag: Nectin-4

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

Antibody-drug conjugates (ADCs) have become a mainstay in targeted cancer therapies, but their effectiveness can be limited by tumor antigen heterogeneity and acquired resistance.

Antibody-Drug Conjugates in Gastric Cancer: Clinical Progress, Resistance, and the Road Ahead

FDA Grants Fast Track Designation ADRX-0706, a Nectin-4 ADC for the Treatment of Advanced Cervical Cancer

During the upcoming 2024 annual meeting of the American Society of Clinical Oncology (ASCO) Annual Meeting, been held from May 31st - June 4th, Astellas...

Preclinical data for ADRX-0706, a fully proprietary investigational antibody=drug conjugate or ADC being developed by Adcentrx, will be presented at the American Association for Cancer...

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for priority review for enfortumab vedotin-ejfv (Padcev® ; Astellas/Seagen with pembrolizumab (Keytryuda® ( Merck & Co; Merck Sharp & Dohme/MSD) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body.

Dosing has begun in a Phase 1 clinical study evaluating BAT8007, an antibody-drug conjugate (ADC) that targets Nectin-4 being developed by Guangzhou, China-based Bio-Thera...

Corbus Pharmaceuticals, a precision oncology company, today announced that it has entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical, a subsidiary of...

Cisplatin-based combination chemotherapy has been widely accepted as the first-line treatment option for cisplatin-eligible patients diagnosed with locally advanced or metastatic urothelial cancer (mUC)...